Norgestimate/Ethinyl Estradiol Tablets
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DLA TROOP SUPPORT
Contract Value
Not provided
Codes & Classification
Solicitation Number
SPE2D2-25-D-0009
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
Documents2
The Defense Logistics Agency (DLA) Troop Support, operating under the Department of Defense, has issued an award notice for contract SPE2D2-25-D-0009, pertaining to the supply of Norgestimate/Ethinyl Estradiol Tablets. This notice specifically announces the exercise of Option Year 1, which will be effective from April 27, 2026, through April 26, 2027. The contract supports the ongoing requirement for pharmaceutical preparations, with a focus on the provision of these oral contraceptive tablets.
The scope of this procurement centers on the manufacturing and delivery of Norgestimate/Ethinyl Estradiol Tablets, classified under NAICS code 325412 (Pharmaceutical Preparation Manufacturing, 2022 version) and Product Service Code 6505 (Drugs and Biologicals). The place of performance is identified as Villaquilambre, Spain, indicating that the manufacturing or distribution activities will be conducted at this location.
The intended outcome of this contract is to ensure a reliable and consistent supply of Norgestimate/Ethinyl Estradiol Tablets to meet the needs of the Department of Defense. The award reflects DLA Troop Support’s commitment to maintaining the availability of essential pharmaceuticals for its stakeholders.
Key requirements for this contract include adherence to all applicable pharmaceutical manufacturing standards and regulations, as well as the ability to deliver the specified product within the agreed performance period. Contractors are expected to maintain high quality and compliance standards throughout the contract lifecycle.
The contracting entity for this procurement is DLA Troop Support, a federal office within the Defense Logistics Agency. The primary point of contact for this award is Kyle Lewicki ([email protected], phone: 4457370977), with Jason Wray ([email protected], phone: 4457376304) listed as the secondary contact. Interested parties can reference the official notice and related attachments via the SAM.gov opportunity ID f9d32774094d472fbda9c0ee00c176a6.
This award notice is currently active and was posted on March 26, 2026. Contractors evaluating this opportunity should note that it is an exercised option under an existing contract, rather than a new solicitation. No set-aside requirements or special considerations are specified in the provided information. The contract is expected to maintain consistent requirements and deliverables throughout its duration, focusing on the uninterrupted supply of the designated pharmaceutical product.